AndreyPopov / iStockphoto.com
Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, Hospira, patent, patent infringement, biosimilar, Biologics Price Competition and Innovation Act, anaemia